MedTrace Logo

Interval Training in Young Healthy Individuals

NCT00733941 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-05-27

No results posted yet for this study

Summary

Individuals who participate in regular physical exercise possess a lower prevalence of cardiovascular risk factors such as hypertension, type 2 diabetes, obesity and hypercholesterolemia, and aerobic exercise is therefore considered an important adjuvant therapy in risk factor modification and to promote health.

The main focus of the present study is therefore to detect how rapid it is possible to increase aerobic capacity with interval running exercise.

The hypothesis is that it is possible to improve maximal oxygen uptake faster when increasing training frequency. The total gain in maximal oxygen uptake will however be the same between the two groups when they have performed the same amount of training

Conditions

  • Healthy Subjects
  • Exercise Test

Interventions

BEHAVIORAL

High frequency training

24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining

BEHAVIORAL

normal frequence training

24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining

Sponsors & Collaborators

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Øivind Rognmo, PhD · Norwegian University of Science and Technology

  • Ulrik Wisløff, Professor · National Taiwan Normal University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
27 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-06-30
Completion
2009-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00733941 on ClinicalTrials.gov